# TCG Crossover Management, LLC: Form 13F holdings

An institutional investment manager in PALO ALTO, CA. SEC CIK 1839948.

- Quarter ended: 2026-06-30
- Filed: 2026-08-14
- Reported value: $4.16bn
- Positions: 54 (54 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/1839948/000121465926010290/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [ABIVAX SA AMERICAN DEPOSITARY SHARES (ABVX)](/companies/abvx.md) | COMM | $800.6m | 19.2% | 6,007,834 |  | Reduced −473,251 |
| [TANGO THERAPEUTICS INC (TNGX)](/companies/tngx.md) | COMM | $283.9m | 6.8% | 9,081,201 |  | Reduced −1,449,870 |
| [CG ONCOLOGY INC (CGON)](/companies/cgon.md) | COMM | $260.8m | 6.3% | 3,670,206 |  | Unchanged |
| [COGENT BIOSCIENCES INC (COGT)](/companies/cogt.md) | COMM | $187.9m | 4.5% | 4,854,436 |  | Reduced −92,458 |
| [IMMUNOVANT INC (IMVT)](/companies/imvt.md) | COMM | $171.8m | 4.1% | 4,457,988 |  | Unchanged |
| [SPYRE THERAPEUTICS INC (SYRE)](/companies/syre.md) | COMM | $168.7m | 4.1% | 1,900,582 |  | Unchanged |
| [DIANTHUS THERAPEUTICS INC (DNTH)](/companies/dnth.md) | COMM | $163.4m | 3.9% | 1,676,624 |  | Unchanged |
| [MIRUM PHARMACEUTICALS INC (MIRM)](/companies/mirm.md) | COMM | $124.3m | 3.0% | 1,062,049 |  | Unchanged |
| [ZAI LAB LTD-ADR (ZLAB)](/companies/zlab.md) | ADRS | $116.6m | 2.8% | 6,137,627 |  | New +6,137,627 |
| [AMYLYX PHARMACEUTICALS INC (AMLX)](/companies/amlx.md) | COMM | $112.1m | 2.7% | 6,243,812 |  | Unchanged |
| [MONTE ROSA THERAPEUTICS INC (GLUE)](/companies/glue.md) | COMM | $111.9m | 2.7% | 4,622,151 |  | Unchanged |
| [BIOCRYST PHARMACEUTICALS INC (BCRX)](/companies/bcrx.md) | COMM | $110.2m | 2.6% | 11,020,968 |  | Unchanged |
| [VOR BIOPHARMA INC (VOR)](/companies/vor.md) | COMM | $104.4m | 2.5% | 5,673,078 |  | Unchanged |
| [TYRA BIOSCIENCES INC (TYRA)](/companies/tyra.md) | COMM | $103.8m | 2.5% | 3,248,980 |  | Unchanged |
| [DYNE THERAPEUTICS INC (DYN)](/companies/dyn.md) | COMM | $102.5m | 2.5% | 4,615,144 |  | Unchanged |
| [DISC MEDICINE INC (IRON)](/companies/iron.md) | COMM | $98.1m | 2.4% | 1,341,862 |  | Unchanged |
| [RELAY THERAPEUTICS INC (RLAY)](/companies/rlay.md) | COMM | $80.0m | 1.9% | 4,273,356 |  | Unchanged |
| [SAVARA INC (SVRA)](/companies/svra.md) | COMM | $76.2m | 1.8% | 12,362,205 |  | Unchanged |
| [AURA BIOSCIENCES INC (AURA)](/companies/aura.md) | COMM | $67.7m | 1.6% | 9,533,333 |  | New +9,533,333 |
| [REVOLUTION MEDICINES INC (RVMD)](/companies/rvmd.md) | COMM | $63.8m | 1.5% | 340,899 |  | Reduced −235,574 |
| [FIRST TRACKS BIOTHERAPEUTICS (TRAX)](/companies/trax.md) | COMM | $58.3m | 1.4% | 2,895,304 |  | New +2,895,304 |
| [KODIAK SCIENCES INC (KOD)](/companies/kod.md) | COMM | $56.3m | 1.4% | 1,445,538 |  | Unchanged |
| [AVALO THERAPEUTICS INC (AVTX)](/companies/avtx.md) | COMM | $55.8m | 1.3% | 3,017,120 |  | Added +2,278,737 |
| [LB PHARMACEUTICALS INC (LBRX)](/companies/lbrx.md) | COMM | $47.0m | 1.1% | 1,447,310 |  | Reduced −392,179 |
| [CENTURY THERAPEUTICS INC (IPSC)](/companies/ipsc.md) | COMM | $43.4m | 1.0% | 17,754,430 |  | Unchanged |
| [TECTONIC THERAPEUTIC INC (TECX)](/companies/tecx.md) | COMM | $41.4m | 1.0% | 1,204,891 |  | Unchanged |
| [XENCOR INC (XNCR)](/companies/xncr.md) | COMM | $39.5m | 0.9% | 2,452,138 |  | Unchanged |
| [SURROZEN INC (SRZN)](/companies/srzn.md) | COMM | $38.2m | 0.9% | 1,473,101 |  | Unchanged |
| [EDITAS MEDICINE INC (EDIT)](/companies/edit.md) | COMM | $36.0m | 0.9% | 11,111,111 |  | New +11,111,111 |
| [MBX BIOSCIENCES INC (MBX)](/companies/mbx.md) | COMM | $35.9m | 0.9% | 650,000 |  | Unchanged |
| PHARVARIS BV | COMM | $34.9m | 0.8% | 1,008,229 |  | New +1,008,229 |
| [SILENCE THERAPEUTICS PLC (SLN)](/companies/sln.md) | ADRS | $33.3m | 0.8% | 3,033,560 |  | Unchanged |
| INFLARX N V | COMM | $32.5m | 0.8% | 14,500,000 |  | New +14,500,000 |
| [ALTIMMUNE INC (ALT)](/companies/alt.md) | COMM | $30.4m | 0.7% | 10,000,000 |  | New +10,000,000 |
| [JANUX THERAPEUTICS INC (JANX)](/companies/janx.md) | COMM | $27.5m | 0.7% | 1,789,617 |  | Unchanged |
| [PERSPECTIVE THERAPEUTICS INC (CATX)](/companies/catx.md) | COMM | $27.0m | 0.6% | 7,915,567 |  | Unchanged |
| [AGOMAB THERAPEUTICS NV (AGMB)](/companies/agmb.md) | ADRS | $26.7m | 0.6% | 2,053,233 |  | Unchanged |
| BIOHAVEN LTD | COMM | $26.5m | 0.6% | 1,779,952 |  | Reduced −2,851,365 |
| [AKTIS ONCOLOGY INC (AKTS)](/companies/akts.md) | COMM | $22.5m | 0.5% | 696,560 |  | New +696,560 |
| [ALECTOR INC (ALEC)](/companies/alec.md) | COMM | $20.1m | 0.5% | 10,000,000 |  | Unchanged |
| FORTE BIOSCIENCES INC | COMM | $19.6m | 0.5% | 920,000 |  | New +920,000 |
| [MONOPAR THERAPEUTICS INC (MNPR)](/companies/mnpr.md) | COMM | $18.8m | 0.5% | 203,327 |  | Added +71,224 |
| [OCULAR THERAPEUTIX INC (OCUL)](/companies/ocul.md) | COMM | $16.2m | 0.4% | 1,647,752 |  | Unchanged |
| ADC THERAPEUTICS SA | COMM | $12.2m | 0.3% | 11,390,175 |  | Unchanged |
| [ALX ONCOLOGY HOLDINGS INC (ALXO)](/companies/alxo.md) | COMM | $11.7m | 0.3% | 5,655,487 |  | Reduced −7,356,362 |
| [ENTRADA THERAPEUTICS INC (TRDA)](/companies/trda.md) | COMM | $7.8m | 0.2% | 1,060,230 |  | Reduced −1,227,270 |
| [CULLINAN THERAPEUTICS INC (CGEM)](/companies/cgem.md) | COMM | $7.4m | 0.2% | 406,786 |  | Unchanged |
| [ARVINAS HOLDING CO LLC (ARVN)](/companies/arvn.md) | COMM | $5.9m | 0.1% | 707,098 |  | Reduced −1,680,363 |
| [KORRO BIO INC (KRRO)](/companies/krro.md) | COMM | $5.5m | 0.1% | 416,301 |  | Unchanged |
| RESEARCH ALLIANCE CORP CL A | COMM | $5.3m | 0.1% | 500,000 |  | New +500,000 |
| [LEONABIO INC (LONA)](/companies/lona.md) | COMM | $4.3m | 0.1% | 464,398 |  | Unchanged |
| JATT II ACQUISITION CORP | COMM | $2.3m | <0.1% | 200,000 |  | New +200,000 |
| [CONTEXT THERAPEUTICS INC (CNTX)](/companies/cntx.md) | COMM | $1.5m | <0.1% | 2,682,696 |  | Unchanged |
| [EIKON THERAPEUTICS INC (EIKN)](/companies/eikn.md) | COMM | $494.6k | <0.1% | 37,902 |  | New +37,902 |

## Sold out

Held at the end of the quarter before and not reported this quarter.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| CENTESSA PHARMACEUTICALS PLC | ADRS | $0 | 0.0% | 0 |  | Sold out −4,286,480 |
| [FULCRUM THERAPEUTICS INC (FULC)](/companies/fulc.md) | COMM | $0 | 0.0% | 0 |  | Sold out −5,250,000 |
| [LIQUIDIA TECHNOLOGIES INC (LQDA)](/companies/lqda.md) | COMM | $0 | 0.0% | 0 |  | Sold out −403,048 |
| [STRUCTURE THERAPEUTICS INC (GPCR)](/companies/gpcr.md) | ADRS | $0 | 0.0% | 0 |  | Sold out −140,411 |
| [UPSTREAM BIO INC (UPB)](/companies/upb.md) | COMM | $0 | 0.0% | 0 |  | Sold out −181,063 |
| UROGEN PHARMA LTD | COMM | $0 | 0.0% | 0 |  | Sold out −405,365 |
| [VISTAGEN THERAPEUTICS INC (VTGN)](/companies/vtgn.md) | COMM | $0 | 0.0% | 0 |  | Sold out −2,676,580 |

Source: SEC EDGAR, Form 13F-HR, accession 0001214659-26-010290. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.